Answers are grounded in this paper and cite their sources.
Investigates enzyme activity and surface expression in cells using engineered CD73 mutants, indicating their potential for cancer therapies.
NT5E, a 5′ Ectonucleotidase, is an emerging hotspot for cancer immunotherapies. However, available enzymatic inhibitors have shown limited promise, indicating activity-independent roles. Delineating activity-dependent and independent roles of this protein with precision requisites identification of critical residues impacting activity without hampering surface expression/stability. Conserved Phenylalanine (F) at 417 and 500 positions, which form a π stack with substrate-AMP, was chosen as the region of interest for in silico mutagenesis. F417 and F500 were mutated to Valine (V) individually using Missense3D to obviate broad structural damage. CD73-F417V/F500V dual mutant was then subjected to Molecular Dynamics simulations for prediction of stability and structural variations in the protein over time in comparison to wild-type crystal structure. Gibbs Free energy indicated a significant decrease in ligand binding affinity of CD73-F417V/F500V. RMSD and RMSF analysis of MD trajectories indicated increased mobility, suggesting weaker ligand binding affinity within the catalytic site of the mutant potentially impacting functional dynamics and protein-ligand contacts. Overexpression of CD73-F417V/F500V mutant in CD73 null-HEKs indicated stable surface expression but complete loss of Ecto-nucleotidase activity, thus providing a tool to dissect activity-dependent and independent functions of NT5E.
No takes yet. Share an insight, caveat, or question.
Mohan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: